BIOTRONIK has started enrolling patients for its BioInsight clinical study of the BioMonitor 2 insertion procedure in an office setting.

BioMonitor 2 is an insertable cardiac remote monitor based on ProMRI technology, it is placed underneath a patient's skin to track evidence of suspected cardiac arrhythmia or unexplained syncope.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The insertable cardiac monitor has been designed to facilitate accurate detection of arrhythmias by delivering good signal quality.

BioMonitor 2 enables reliable and continuous arrhythmia monitoring with automatic, daily transmissions and highly efficient alert management.

The device can also be used for the monitoring of atrial fibrillation in patients who have undergone ablation procedures.

See Also:

The BioInsight study is being conducted as a multi-centre, prospective, non-randomised post-market study intended to assess the safety and feasibility of performing the minimally invasive BioMonitor 2 insertion procedure in an office setting.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the study, the subjects will receive BioMonitor 2 via in-office insertion and will be examined for 90 days to monitor for any potential adverse events, including infection and bleeding.

BIOTRONIK president Marlou Janssen said: "BioMonitor 2 has been rapidly adopted by physicians, becoming a trusted, reliable solution to monitor for cardiac arrhythmias.

"The BioInsight study will assure physicians and patients that performing the insertion procedure in an office setting safely and effectively improves access to this critical diagnostic tool."

"There is a significant need for BioMonitor 2, and we want to ensure our physicians have the utmost confidence in their ability to deliver efficient patient care.

“The BioInsight study will assure physicians and patients that performing the insertion procedure in an office setting safely and effectively improves access to this critical diagnostic tool."

The study is slated to be completed in the third quarter of next year.

Image: The BioMonitor 2. Photo: courtesy of BIOTRONIK.